Neurodivergence, together with Consideration Deficit-Hyperactivity Dysfunction (ADHD), stays an space of nice curiosity throughout social media, with excessive ranges of misinformation being unfold on totally different on-line platforms (Carter et al., 2026), as blogged lately by Higson-Sweeney (2026). Regardless of this, there have been no elves running a blog on the remedy of ADHD since our final journey into the woodland earlier this 12 months (Budgen & Suetani, 2026; Zhang et al., 2025).
To not be discouraged, we’ve returned to debate an thrilling community meta-analysis from Nourredine et al. (2026). Pharmacological remedy is efficient for ADHD, however particular steerage on dosing is proscribed. Generally we don’t know if the dose is just too little or an excessive amount of. On one hand, there may be concern that clinicians could also be participating in therapeutic inertia – prescribing suboptimal doses the place growing could also be simpler. Then again, we could danger growing the dose past what’s protected or crucial for maximal efficacy. Earlier dose-effect research examined licensed doses in particular age teams with out a community meta-analysis, that means it was solely doable to discover direct comparability with placebo.
That is the primary dose-effect community meta-analysis throughout age teams for ADHD. The authors examined a broad dataset, together with information past licensed doses, to estimate efficacy and tolerability throughout dosages and age teams. This examine makes an attempt to shed some much-needed mild on the Goldilocks zone – the doses ‘excellent’ for folks with ADHD.
The outcomes of this examine help clinicians in weighing the dangers and advantages when adjusting doses for medicine remedy of ADHD.
Strategies
Eligible articles have been obtained via the MED-ADHD database, a complete repository of double-blind randomised managed trials (RCTs). RCTs with parallel-group or crossover designs utilizing pharmacological monotherapy for at the least 1 week have been included. Members have been aged ≥5 with a analysis of ADHD primarily based on Diagnostic and Statistical Handbook of Psychological Problems, Third Version (DSM-III) or later, or equal Worldwide Classification of Ailments (ICD) standards. Notably, research that mixed pharmacotherapy and psychotherapy have been excluded.
Eligible drugs included amphetamines, atomoxetine, bupropion, clonidine, dexmethylphenidate, guanfacine, methylphenidate, modafinil and viloxazine. The dosages for amphetamines have been transformed to dextroamphetamine-equivalents and methylphenidate was transformed to immediate-release methylphenidate hydrochloride primarily based on the conversion components from Farhat et al. (2022). The reported doses are the utmost meant goal dose within the examine, not essentially the dose acquired by members.
To evaluate the severity of ADHD signs, the authors extracted score scale measures (e.g. SNAP or Conners) and expressed these as a standardised imply distinction (SMD). To evaluate tolerability, the danger of dropout was calculated and expressed as an odds ratio (OR). As a result of this was a Bayesian evaluation, uncertainty is reported as 95% credible intervals (CrI) relatively than confidence intervals: the vary inside which we could be 95% sure the true impact lies.
Outcomes
15,096 references have been discovered on preliminary screening, with 164 research included within the systematic evaluate and 113 research (68 for youngsters and adolescents and 45 for adults) have been included within the community meta-analysis. There have been a complete of 14,138 kids or adolescents with a imply age of 11 (70.6% male) and 11,016 adults with a imply age of 36 (54.0% male). The principle findings are summarised beneath:
Kids and Adolescents
Eighteen fixed-dose RCTs with a complete of 4,159 kids or adolescents have been included within the efficacy evaluation. The tolerability evaluation included information from 65 RCTs with a complete of 13,972 people.
- Methylphenidate reached peak efficacy at 45mg/day (SMD −0.89; 95% CrI −1.18 to −0.60).
- Most danger of discontinuation was 2.7% (95% CrI 1.4 to five.1) at 50mg/day. Apparently, growing the dose past the licensed most didn’t elevate the discontinuation danger, however precision was low.
- Amphetamines reached peak efficacy at 25mg/day (SMD -1.06; 95% CrI -1.35 to -0.78).
- There was a linear discontinuation danger with the danger exceeding placebo at doses above 25mg/day.
- Lisdexamfetamine was separated with a peak efficacy at roughly 55mg/day (SMD -1.05; 95% CrI -1.4 to -0.69). Based mostly on the conversion components, that is roughly equal to 25mg/day of amphetamines.
- Guanfacine reached peak efficacy at 4mg/day (SMD -0.66; 95% CrI -0.99 to -0.31)
- Discontinuation danger elevated as much as 4mg/day, reaching a median danger of 9.8% (95% CrI 4.4 to twenty). Though the danger appeared to lower following this, with very low certainty.
Inclusion of flexible-dose trials yielded related outcomes. These trials included information for dosing at an equal 93mg/day methylphenidate with a steered decline in efficacy.
Adults
11 fixed-dose RCTs with 2,450 people included within the efficacy evaluation. The tolerability evaluation included information from 42 RCTs with a complete of 10,463 adults.
- Amphetamines reached a plateau at 50mg/day (SMD -0.74; 95% CrI -1.26 to -0.2).
- Observe that the utmost licensed dose by the FDA is 40mg/day
- Danger of discontinuation exceeded placebo (2.6%; 95% CrI 1.8 to three.6) at 50mg/day and continued to extend with dose.
- Methylphenidate efficacy appeared to extend with escalating doses, however there have been marginal positive aspects above roughly 50mg/day.
- Danger of discontinuation exceeded placebo at 50mg/day
- On the most FDA licensed dose of 60mg, the danger of discontinuation elevated to 7.3% (95% CrI 4.3 to 12).
Inclusion of flexible-dose trials expanded the dataset to five,025 adults, and the dose-effect profiles remained unchanged, albeit with narrower credible intervals.
The findings counsel that for a lot of ADHD drugs, the simplest dose could also be beneath the licensed most and going past this level was not well-tolerated.
Conclusions
The authors concluded:
Our findings problem each therapeutic inertia — accepting suboptimal response with out additional dose titration — and uncritical dose escalation past licensed limits, when potential harms outweigh anticipated advantages.
This analysis means that the simplest ADHD medicine dose typically sits beneath the licensed most, and going increased tends so as to add danger, not profit.
Strengths and limitations
There are numerous strengths on this examine attributable to its strong design. Most significantly, the inclusion standards have been rigorous within the requirement for double-blind RCT research with analysis of ADHD primarily based on recognised requirements (DSM & ICD) and a give attention to fixed-dose trials. This slender definition has resulted in a inhabitants much less reflective of these seen in scientific settings. Nevertheless, it’s an applicable place to begin to cut back the danger of bias and assist within the interpretation of outcomes. Whereas many included trials had a excessive danger of bias, sensitivity evaluation excluding these didn’t change the outcomes, supporting the robustness of the findings.
The authors establish a number of limitations with their examine and talk about the restricted vary of doses (notably in grownup research), heterogeneous score scales for efficacy, lack of capability to conduct subgroup analyses, incapability to evaluate the impression of severity, brief period of research and restricted generalisability to scientific populations. Particularly, the authors stress that the outcomes from the examine are legitimate at a bunch degree, however shouldn’t be used to tell decision-making on the particular person affected person degree attributable to variability in response to drugs. We might spotlight the brief durations of the included research (a imply of seven weeks for adults) as a outstanding limitation of this paper. ADHD is a lifelong situation, and many individuals select to proceed pharmacological remedy long-term. Adversarial results with long-term use of psychostimulants usually are not properly outlined, notably for adults, the place there can be growing issues for cardiovascular unintended effects with longer use at increased doses. These dangers usually are not captured within the included research as a result of brief durations.
We additionally stress the constraints as a result of comparatively restricted information for adults. There have been far fewer people within the grownup evaluation compared to kids and adolescents, leading to much less precision within the dose-effect curves, with widening credible intervals at increased doses. Particularly, the amphetamine dose-effect evaluation consisted of knowledge from 459 people, with nearly half (225) receiving a dosage above 40mg/day dextroamphetamine-equivalent. If there have been extra people included within the evaluation, it might be fascinating to see how the dose-effect curves would change and if these would replicate the U-shaped curves seen within the youngster and adolescent cohort. Using dose conversion to dextroamphetamine-equivalents was crucial as a result of restricted dataset; nonetheless, the conversions could have affected the outcomes, as totally different formulations could not have comparable efficacy at these doses. It must also be famous that of the 459 people uncovered to amphetamines, 437 acquired combined amphetamine salts in an extended-release formulation and 22 acquired dextro-amphetamine in an instantaneous launch formulation. No people acquired lisdexamfetamine or dexamfetamine; two drugs generally prescribed in Australia.
The rigorous examine design strengthens the findings, although the brief examine durations and restricted grownup information could limit its scientific applicability at current.
Implications for observe
This examine builds on the dose-effect responses seen within the meta-analyses by Farhat et al. (2022 & 2024) via incorporating oblique proof with the methodology of a community meta-analysis. The outcomes are fascinating and problem frequent scientific observe the place prescribers could cease growing dosages when gentle antagonistic results are encountered, doubtlessly lacking out on peak efficacy. Concurrently, it cautions in opposition to venturing too far into the hazard zone, prescribing increased doses that could not present elevated profit for folks with ADHD. Many scientific tips are likely to assist an individualised strategy of accelerating dosages so long as there may be symptom enchancment and no insupportable antagonistic results. This examine provides to this via discovering that additional will increase past 45mg for methylphenidate and 25mg for amphetamines are unlikely to convey profit and should in reality improve the danger of hurt. For adults, an analogous dose-dependent improve in efficacy is seen, reaching a plateau at roughly 50mg for each methylphenidate and amphetamines, with growing dangers past this. Notably, the dose of amphetamines is above the FDA-licensed most dose, presumably elevating the notion that doses above these licensed for amphetamines could convey elevated profit on the inhabitants degree.
This examine takes a step additional in direction of a larger understanding of efficient dosing within the remedy of ADHD. In beginning to outline the response throughout doses, we’re transferring a lot nearer in direction of the purpose of knowledgeable prescribing and observe. How distant are we from having clear tips akin to these for antidepressants and antipsychotics with outlined minimal efficient doses and steered limits above which there’s unlikely to be profit for many sufferers? We’ve a wealth of this info for different psychotropic drugs; it’s time that we develop this for ADHD drugs.
At a neighborhood degree, in Australia, it’s troublesome to know the best way to translate this information into observe, notably for adults. Right here, lisdexamfetamine is the second mostly prescribed psychostimulant (AIHW, 2025). Changing the outcomes from this examine, maximal efficacy could also be seen with lisdexamfetamine at roughly 110mg. This dose is much past the 70mg most accredited in most jurisdictions in Australia (AADPA, 2026). Ought to we then be growing the dosage for all adults, so far as tolerated, to the utmost allowed? At this stage, the proof doesn’t assist this observe, given the clear lack of long-term tolerance information in adults and the absence of lisdexamfetamine formulations within the evaluation.
In the end, this examine from Nourredine et al. (2026) paves a brand new path in direction of growing precision with ADHD pharmacological administration and will increase our information of efficient dosing. Additional analysis is now wanted to handle the gaps in long-term tolerance and to supply extra information throughout a broader vary of medicines and doses. In the future sooner or later, we hope that it will likely be simpler to seek out the medicine dose ‘excellent’ for folks with ADHD with out the necessity for trial and error like Goldilocks trying to find her porridge.
The outcomes from Nourredine et al. (2026) pave the best way to an improved understanding of the dose-effect fashions for ADHD drugs.
Assertion of pursuits
Jordan Budgen has no conflicting pursuits with respect to the content material of this weblog put up.
Shuichi Suetani is a member of the Royal Australian and New Zealand School of Psychiatrists ADHD Community, and Australasian ADHD Professionals Affiliation.
Hyperlinks
Main paper
Mikail Nourredine, Lucie Jurek, Tasnim Hamza, Andrea Cipriani, Fabien Subtil, Valeria Parlatini, Luis Farhat, Guilherme Fusetto Veronesi, Orestis Efthimiou, Georgia Salanti, Samuele Cortese (2026) Pharmacological interventions for ADHD: a scientific evaluate and dose–impact community meta-analysis. The Lancet Psychiatry, 13, 485-495.
Different references
Australasian ADHD Professionals Affiliation (AADPA) (2026). ADHD Treatment Prescribing Laws & Authorities in Australia & New Zealand.
Australian Institute of Well being and Welfare (AIHW) (2025). ADHD Drugs allotted 2004-05 to 2023-24.
Budgen J & Suetani S. Treatment impression on non-core ADHD signs and hurt prevention. The Psychological Elf, 21 Jan 2026.
Farhat L.C., Flores J.M., Behling E. et al. (2022) The results of stimulant dose and dosing technique on remedy outcomes in attention-deficit/hyperactivity dysfunction in kids and adolescents: a meta-analysis. Mol Psychiatry 27, 1562–1572.
Farhat, L. C., Flores, J. M., Avila-Quintero, V. J., Polanczyk, G. V., Cipriani, A., Furukawa, T. A., Bloch, M. H., & Cortese, S. (2024). Remedy Outcomes With Licensed and Unlicensed Stimulant Doses for Adults With Consideration-Deficit/Hyperactivity Dysfunction: A Systematic Assessment and Meta-Evaluation. JAMA psychiatry, 81(2), 157–166.
Higson-Sweeney N. Scrolling for solutions: how dependable is psychological well being and neurodivergence-related info on social media? – Nationwide Elf Service. The Psychological Elf, 22 Apr 2026.
